CN115552006A - 用于mapt调节的寡核苷酸 - Google Patents
用于mapt调节的寡核苷酸 Download PDFInfo
- Publication number
- CN115552006A CN115552006A CN202180034587.6A CN202180034587A CN115552006A CN 115552006 A CN115552006 A CN 115552006A CN 202180034587 A CN202180034587 A CN 202180034587A CN 115552006 A CN115552006 A CN 115552006A
- Authority
- CN
- China
- Prior art keywords
- nucleotides
- antisense strand
- dsrna
- sense strand
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991405P | 2020-03-18 | 2020-03-18 | |
| US62/991,405 | 2020-03-18 | ||
| US202063071106P | 2020-08-27 | 2020-08-27 | |
| US63/071,106 | 2020-08-27 | ||
| PCT/US2021/022688 WO2021188626A1 (en) | 2020-03-18 | 2021-03-17 | Oligonucleotides for mapt modulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115552006A true CN115552006A (zh) | 2022-12-30 |
Family
ID=77768304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180034587.6A Pending CN115552006A (zh) | 2020-03-18 | 2021-03-17 | 用于mapt调节的寡核苷酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210363523A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121537A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023518439A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230004448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115552006A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021238319A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3171246A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188626A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026390A1 (zh) * | 2023-08-01 | 2025-02-06 | 上海拓界生物医药科技有限公司 | 靶向MAPT的dsRNA及其医药用途 |
| WO2025077806A1 (en) * | 2023-10-11 | 2025-04-17 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of microtubule associated protein tau (mapt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| JP2023521604A (ja) * | 2020-03-30 | 2023-05-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
| CA3174079A1 (en) | 2020-05-26 | 2021-12-02 | Anastasia Khvorova | Synthetic oligonucleotides having regions of block and cluster modifications |
| KR20240067943A (ko) * | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| US20250340872A1 (en) * | 2021-10-07 | 2025-11-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing tau expression |
| MX2024007056A (es) * | 2021-12-13 | 2024-06-24 | Lilly Co Eli | Agentes de interferencia de arn de mapt. |
| US20250171777A1 (en) * | 2022-02-11 | 2025-05-29 | Alnylam Pharmaceuticals, Inc. | Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof |
| US20230392146A1 (en) * | 2022-03-11 | 2023-12-07 | University Of Massachusetts | Oligonucleotides for app modulation |
| WO2023193004A2 (en) * | 2022-04-01 | 2023-10-05 | Triplet Therapeutics, Inc. | Methods for the treatment of neurodegenerative disorders |
| CA3247389A1 (en) * | 2022-05-12 | 2023-11-16 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MAPT |
| CA3246379A1 (en) * | 2022-05-13 | 2023-11-16 | Julius-Maximilians-Universität Würzburg | METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| WO2024073618A2 (en) * | 2022-09-29 | 2024-04-04 | Atalanta Therapeutics, Inc. | Sirna compositions and methods targeting microtubule associated protein tau nucleic acids |
| WO2024145474A2 (en) * | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024201423A2 (en) * | 2023-03-30 | 2024-10-03 | Biorchestra Co., Ltd. | Microtubule-associated protein tau targeting sirnas and uses thereof |
| EP4698652A2 (en) * | 2023-04-20 | 2026-02-25 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| WO2025212467A1 (en) * | 2024-03-31 | 2025-10-09 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use |
| WO2025233849A2 (en) * | 2024-05-07 | 2025-11-13 | Janssen Pharmaceutica Nv | MAPT siRNA AND USES THEREOF |
| US20260167963A1 (en) * | 2024-08-29 | 2026-06-18 | Synerk Inc. | Compounds, Compositions and Methods for Reducing MAPT (TAU) Expression |
| WO2026090357A1 (en) * | 2024-10-24 | 2026-04-30 | Adarx Pharmaceuticals, Inc. | Mapt-modulating oligonucleotides for treating central nervous system diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107789A2 (en) * | 2006-03-17 | 2007-09-27 | Sylentis S.A. | Treatment of cns conditions |
| CN101115846A (zh) * | 2004-10-27 | 2008-01-30 | 范德比尔特大学 | 与感染相关的哺乳动物基因 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| WO2008124066A1 (en) * | 2007-04-05 | 2008-10-16 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| TWI702046B (zh) * | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| ES2820713T3 (es) * | 2015-03-25 | 2021-04-22 | Univ Degli Studi Di Trento | Terapia mediada por ARN interferente para enfermedades neurodegenerativas |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017132669A1 (en) * | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2020041769A1 (en) * | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
-
2021
- 2021-03-17 JP JP2022556142A patent/JP2023518439A/ja active Pending
- 2021-03-17 MX MX2022011516A patent/MX2022011516A/es unknown
- 2021-03-17 KR KR1020227031792A patent/KR20230004448A/ko active Pending
- 2021-03-17 AU AU2021238319A patent/AU2021238319A1/en active Pending
- 2021-03-17 CN CN202180034587.6A patent/CN115552006A/zh active Pending
- 2021-03-17 WO PCT/US2021/022688 patent/WO2021188626A1/en not_active Ceased
- 2021-03-17 US US17/204,480 patent/US20210363523A1/en not_active Abandoned
- 2021-03-17 EP EP21770963.3A patent/EP4121537A4/en active Pending
- 2021-03-17 CA CA3171246A patent/CA3171246A1/en active Pending
-
2025
- 2025-09-24 US US19/338,285 patent/US20260109982A1/en active Pending
-
2026
- 2026-02-20 JP JP2026025899A patent/JP2026106461A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101115846A (zh) * | 2004-10-27 | 2008-01-30 | 范德比尔特大学 | 与感染相关的哺乳动物基因 |
| WO2007107789A2 (en) * | 2006-03-17 | 2007-09-27 | Sylentis S.A. | Treatment of cns conditions |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026390A1 (zh) * | 2023-08-01 | 2025-02-06 | 上海拓界生物医药科技有限公司 | 靶向MAPT的dsRNA及其医药用途 |
| WO2025077806A1 (en) * | 2023-10-11 | 2025-04-17 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of microtubule associated protein tau (mapt) |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518439A (ja) | 2023-05-01 |
| MX2022011516A (es) | 2023-01-04 |
| AU2021238319A1 (en) | 2022-10-06 |
| EP4121537A4 (en) | 2024-07-31 |
| EP4121537A1 (en) | 2023-01-25 |
| WO2021188626A1 (en) | 2021-09-23 |
| JP2026106461A (ja) | 2026-06-29 |
| CA3171246A1 (en) | 2021-09-23 |
| US20210363523A1 (en) | 2021-11-25 |
| US20260109982A1 (en) | 2026-04-23 |
| KR20230004448A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260109982A1 (en) | Oligonucleotides for mapt modulation | |
| US20210355491A1 (en) | Oligonucleotides for msh3 modulation | |
| US20230193281A1 (en) | Oligonucleotides for sod1 modulation | |
| US20220090069A1 (en) | Oligonucleotides for htt-1a modulation | |
| JP2025156319A (ja) | 組織特異的なapoe調節のためのオリゴヌクレオチド | |
| US20230313198A1 (en) | Oligonucleotides for mlh3 modulation | |
| US20230340475A1 (en) | Oligonucleotides for mlh1 modulation | |
| CN115698291A (zh) | 用于SARS-CoV-2调节的寡核苷酸 | |
| US20230348907A1 (en) | Oligonucleotides for mecp2 modulation | |
| US20230392146A1 (en) | Oligonucleotides for app modulation | |
| CA3133784A1 (en) | Oligonucleotide-based modulation of c9orf72 | |
| CN115777021A (zh) | 用于snca调节的寡核苷酸 | |
| EP4110913A2 (en) | Oligonucleotides for prnp modulation | |
| US20240301410A1 (en) | Oligonucleotides for htt-1a modulation | |
| US20240052344A1 (en) | Oligonucleotides for pms1 modulation | |
| US20240035027A1 (en) | Oligonucleotides for pms2 modulation | |
| JP2025532983A (ja) | S6k1を標的とするオリゴヌクレオチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |